First Tracks Biotherapeutics Inc

TRAX

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$44.14

+$1.03 · +2.39%

Aug 24, 11:17 AM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

49/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

Expensive

Momentum

Strong Up

Sentiment

Mixed

Risk resilience

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Daniel R. Faga
Listed since: Apr 20, 2026
Employees: 104

Market position

Day range

Current $44.14

$42.55$44.325

52-week range

Current $44.14

$14.72$49.91

Open: $43.47
Previous close: $43.11
Volume: 291.33K; 0.43× average
Average volume: 671.84K; Average daily volume
Market cap: 1.54B USD
Beta: 3.37; Market reference 1
50-day average: $33.0544; +33.54% above average
200-day average: $26.3164; +67.73% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 436.14M USD
P/E (TTM): -15.71×
P/B (TTM): 5.96×
P/S (TTM): 0×
EV / EBITDA: -2.44×
Earnings yield: -25.16%
Free cash flow yield: -21.66%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: -57.77%
Return on assets: -50.25%
Return on invested capital: -59.35%

Financial health

Debt / equity: 0×
Current ratio: 10.2×

Financial statements

Income trends

Operating income

−179.01M USD+1.16%

Net income

−166.09M USD-1.46%

Metric (USD)	FY2025	FY2024	FY2023
Cost of goods sold	139.61M USD	152.35M USD	—
Gross profit	−139.61M USD	−152.35M USD	—
Research and development	139.61M USD	152.35M USD	97.59M USD
Selling, general, and administrative	39.39M USD	28.76M USD	20.87M USD
Operating expenses	39.39M USD	28.76M USD	118.46M USD
Interest income	12.94M USD	17.38M USD	12.31M USD
Depreciation and amortization	559K USD	2.4M USD	2.38M USD
Operating income	−179.01M USD	−181.1M USD	−118.46M USD
Net income	−166.09M USD	−163.71M USD	−106.15M USD